Veliparib for the treatment of ovarian cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012v1.0, cancer incidence and mortality worldwide. IARC CancerBase. 2013;(11).
   Google Scholar
• Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989;96:889–892.
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Stewart L. Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database Syst Rev. 1999;(1). doi:10.1002/14651858.CD001418.
   Google Scholar
• Morrison J, Haldar K, Kehoe S, et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2012;(8). doi:10.1002/14651858.CD005343.
   Web of Science ®Google Scholar
• Wiggans AJ, Cass GKS, Bryant A, et al. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD007929.
   PubMedGoogle Scholar
• Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: a new era of targeted therapy. Maturitas. 2015;81:5–9.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917.
   PubMed Web of Science ®Google Scholar
• Reiss KA, Herman JM, Zahurak M, et al. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015;21:68–76.
   PubMed Web of Science ®Google Scholar
• Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009;52:514–523.
   PubMed Web of Science ®Google Scholar
• Li J, Kim S, Sha X, et al. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin Cancer Res. 2014;20:3931–3944.
   PubMed Web of Science ®Google Scholar
• Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of veliparib (ABT-888), a poly(ADP-ribose)polymerase (PARP) inhibitor in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J Clin Oncol. 2011;29:3041. [Suppl.: abstract 3041].
   Web of Science ®Google Scholar
• Kummar S, Ji J, Morgan R, et al. A Phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18:1762–34.
   Web of Science ®Google Scholar
• Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in Adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2011;71:5626–5634.
   Web of Science ®Google Scholar
• LoRusso P, Ji JJ, Li J, et al. Parchment. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts 2011; Part 1. Vol 29, No 15_supplement.
   Google Scholar
• Puhalla S, Beumer JH, Pahuja S, et al. Final results of a phase 1 syudy of single-agent veliparib in patient with either BRCA1/2-mutated cancer, platinum-refractory ovarian, or basal-like breast cancer. J Clin Oncol. 2014;32:5s. [Abstract 2570].
   PubMed Web of Science ®Google Scholar
• Bell-McGuinn KM, Brady WE, Schilder RJ, et al. A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015;33:5507. (Abstract 5507).
   Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137:386–391.
   PubMed Web of Science ®Google Scholar
• Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014;133:362–369.
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728–2737.
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18:510–523.
   PubMed Web of Science ®Google Scholar
• Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res. 2012;18:1655–1662.
   PubMed Web of Science ®Google Scholar
• Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375–429.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA-carriers. N Engl J Med. 2009;361:123–134.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–1392.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13:433–443.
   PubMed Web of Science ®Google Scholar
• Bertwistle D, Ashworth A. The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology? Breast Cancer Res. 1999;1:41–47.
   PubMedGoogle Scholar
• Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134–1149.
   PubMed Web of Science ®Google Scholar
• Petermann E, Keil C, Oei SL. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol Life Sci. 2005;62:731–738.
   PubMed Web of Science ®Google Scholar
• Hakmé A, Wong H-K, Dantzer F, et al. The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects’ review series. EMBO Rep. 2008;9:1094–1100.
   PubMed Web of Science ®Google Scholar
• D’Amours D, Desnoyers S, D’Silva I, et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342:249–268.
   PubMed Web of Science ®Google Scholar
• Amé J-C, Spenlehauer C, De Murcia G. The PARP superfamily. Bioessays. 2004;26:882–893.
   PubMed Web of Science ®Google Scholar
• Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol). 2004;16:29–39.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Alderson T. New targets for cancer chemotherapy—poly(ADP-ribosylation) processing and polyisoprene metabolism. Biol Rev Camb Philos Soc. 1990;65:623–641.
   PubMed Web of Science ®Google Scholar
• Patela AG, Sarkariab JN, Kaufmanna SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. PNAS. 2011;108:3406–3411.
   PubMed Web of Science ®Google Scholar
• Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13:3033–3042.
   PubMed Web of Science ®Google Scholar
• Shall S, De Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res. 2000;460:1–15.
   PubMed Web of Science ®Google Scholar
• Stewart E, Goshorn R, Bradley C, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014;9:829–841.
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Clin Oncol. 2009;27:2705–2711.
   Web of Science ®Google Scholar
• Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther. 2015;8:1931–1939.
   PubMed Web of Science ®Google Scholar
• Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet. 2014;53:479–488.
   PubMed Web of Science ®Google Scholar
• Li X, Delzer J, Voorman R, et al. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos. 2011;39:1161–1169.
   PubMed Web of Science ®Google Scholar
• Mehta MP, Wang D, Wang F, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol. 2015;122:409–417.
   PubMed Web of Science ®Google Scholar
• Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015;21:1574–1582.
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, phase 2 trial of veliparib (ABT-88) with carboplatin and paclitaxel in previously untreated metastatic or advanced non-small cell lung cancer. 2015. ClinicalTrials.gov Identifier: NCT01560104
   Google Scholar
• I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2). 2015. ClinicalTrials.gov Identifier:NCT01042379.
   Google Scholar
• Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
   PubMed Web of Science ®Google Scholar
• A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2015. ClinicalTrials.gov Identifier:NCT02470585.47.
   Google Scholar
• McNeish IA, Oza AM, Coleman RL, et al. Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol. 2015:33:5508 (suppl; abstr 5508)
   Web of Science ®Google Scholar
• Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med. 2015;8:127–135.
   PubMedGoogle Scholar
• Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21:4257–42561.
   PubMed Web of Science ®Google Scholar
• Musella A, Marchetti C, Gasparri ML, et al. PARP inhibition: a promising therapeutic target in ovarian cancer. Cell Mol Biol. 2015;61:44–61.
   PubMed Web of Science ®Google Scholar
• Nomura H, Kataoka F, Aoki D, et al. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer. Cancer Biomark. 2016;16(1):145–152. doi:10.3233/CBM-150550.
   PubMedGoogle Scholar